Genmab opens the week with a clear consensus picture, shares on NASDAQ radar

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 13:37.

Genmab (DK0010272202) starts the week with a defined analyst view on its NASDAQ-listed biotech shares. Consensus data show a cluster of Buy and Hold ratings with price targets that frame expectations for the Danish antibody specialist, according to MarketBeat and other coverage aggregators.

What the analysts say on Genmab

Genmab shares trade on NASDAQ under the ticker GMAB, giving the Copenhagen-based company access to US biotech capital and analyst coverage from major houses alongside peers such as Regeneron and Novartis. MarketBeat data indicate several Buy recommendations and a smaller group of Hold ratings, summarizing the current consensus stance on the stock.

According to the same MarketBeat overview, analysts have set a range of 12-month price targets for Genmab, defining an implied upside corridor from current levels. The distribution of targets shows cautious optimism on earnings growth from the antibody portfolio, while reflecting typical biotech risk around clinical and commercial execution, as described in market commentary by specialist outlets.

How Genmab compares in biotech

Genmab operates in the global biotech sector, where companies such as Regeneron and Roche also pursue monoclonal antibody-based therapies, giving investors sector benchmarks for valuation multiples and pipeline risk. Consensus-based market commentary highlights Genmab’s established revenue stream and pipeline optionality compared with pure early-stage biotech names, which tend to trade on higher volatility.

On NASDAQ, Genmab’s recent closing price of around 26 US dollars per share on June 26, 2026 situates the company in the mid-cap biotech bracket, based on MarketBeat price data for GMAB. That price level feeds into analyst discounted cash flow and multiples-based models for the stock, providing a reference point for Buy and Hold recommendations.

The product behind the Genmab stock

Genmab generates revenue primarily from antibody-based therapeutics, notably the cancer treatment daratumumab marketed as Darzalex in partnership with Johnson & Johnson, alongside other oncology and immunology candidates in development. The business model combines proprietary discovery platforms with co-development and licensing agreements to share risk and capture royalty streams.

Where the Genmab stock trades today

The Genmab shares (DK0010272202) most actively trade on NASDAQ under the ticker GMAB, where they closed at approximately 26.11 US dollars on 2026-06-26, 15:59 Eastern Time, based on MarketBeat price data. That closing print serves as the current reference point for consensus valuations and sector comparisons.

Disclaimer: This text is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Data and assessments are based on sources cited and may change over time.